XML 12 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
License revenue $ 617  
Revenue, Product and Service [Extensible Enumeration] License  
Operating expenses:    
Research and development expenses $ 19,720 $ 38,785
General and administrative 17,581 16,278
Gain on legal settlement (2,227)  
Restructuring charges 1,276  
Total operating expenses 36,350 55,063
Loss from operations: (35,733) (55,063)
Other income, net:    
Gain on sale of Freeline Therapeutics GmbH 20,279  
Other income, net 73 2,973
Interest income, net 240 335
Benefit from R&D tax credit 464 721
Total other income (expense), net 21,056 4,029
Net loss before income taxes (14,677) (51,034)
Income tax expense (168) (46)
Net loss $ (14,845) $ (51,080)
Net loss per share attributable to ordinary shareholders-basic $ (0.23) $ (0.95)
Net loss per share attributable to ordinary shareholders-diluted $ (0.23) $ (0.95)
Weighted average number of ordinary shares outstanding - Basic 65,140,334 53,587,167
Weighted-average number of ordinary shares outstanding - Diluted 65,140,334 53,587,167